The decision to prescribe should involve individualized risk-benefit assessment, considering the patient's specific autoimmune diagnosis, disease activity, concurrent immunosuppressive medications, and overall health status
Conclusion The absence of noteworthy DIF provides confidence for the use of PROMIS and EORTC to measure CF across sociodemographic subgroups
Early discontinuation, within three months, or reducing doses were common
The one exception: Medicare covers GLP-1 medications when prescribed for FDA-approved indications other than weight loss
[6] The first-line treatment for non-alcoholic fatty liver disease involves lifestyle changes and weight loss
Enhanced blood sugar control Recent studies have shown that tirzepatide demonstrated superior glycemic control particularly in the glycated hemoglobin (HbA1c) levels compared to semaglutide in different doses